Page 2 - Steven Tuch News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Steven tuch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Steven Tuch Today - Breaking & Trending Today

Rallybio Reveals Details of Two Pipeline Programs with the Potential to Transform the Lives of Patients with Rare Diseases

Press release content from Business Wire. The AP news staff was not involved in its creation.
Rallybio Reveals Details of Two Pipeline Programs with the Potential to Transform the Lives of Patients with Rare Diseases
March 2, 2021 GMT
NEW HAVEN, Conn. (BUSINESS WIRE) Mar 2, 2021
Rallybio, a clinical-stage biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the details of two previously undisclosed pipeline programs. RLYB212 is a novel monoclonal antibody to human platelet antigen (HPA)-1a in preclinical development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a potentially life-threatening rare disorder that can cause uncontrolled bleeding in fetuses and newborns. RLYB116 is a small protein inhibitor of complement factor 5 (C5) suitable for subcutaneous administration in preclinical development for the treatme ....

New Haven , United States , Tara Dimilia , Martin Mackay , Steven Tuch , Biovitrum Sobi , European Medicines Agency , Drug Administration , Chief Executive Officer , Steve Uden , Chief Operating Officer , Investigational New Drug , Orphan Drug Designations , Rare Pediatric Disease , Swedish Orphan Biovitrum , Technology Incubation Program , Business Wire , Corporate News , Drug Trials , Products And Services , Health Care Industry , Child And Teen Health , North America , Clinical Trials , Product Testing , Diseases And Conditions ,

New Haven's Next Big Bioscience Star? Former Alexion execs raise $182M for Rallybio

By Natalie Missakian
Just 10 months after Rallybio launched in early 2018, Fierce Biotech, an international trade journal widely followed in the bioscience world, dubbed it one of the year’s 15 most promising biotechs.
The New Haven-based company had yet to make any groundbreaking discoveries. In fact, it didn’t have a single drug in its portfolio. And outside of its announced focus on treatments for severe rare diseases, Rallybio’s founders had offered few details about what medical conditions the startup planned to pursue.
Still, the company was getting noticed not only by reporters covering the industry but also by investors as evidenced by the $37 million it raised shortly after setting up its first lab and office at UConn’s Technology Incubation Program (TIP) in Farmington. ....

New York , United States , New Haven , Pauls Parker , Martin Mackay , Tim Shannon , Steven Tuch , Jeffrey Fryer , Bristol Myers Squibb , Church St , Alexion Pharmaceuticals , Uconn Technology Incubation Program , Fraunhofer Institute , Fierce Biotech , New Haven Based , Technology Incubation Program , Stephen Uden , Canaan Partners , Gold Building , Hartford Business Journal , German Red Cross , Elm City , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , புதியது புகலிடம் , பால்ஸ் பார்க்கர் ,

Chutes & Ladders—GSK vaccine exec Reichman splits to take biotech CEO post

(Pixabay)

Welcome to this week s Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word or the bad from your shop to Fraiser Kansteiner, and we will feature it here at the end of each week.
Another GSK vaccine exec jumps ship for biotech CEO role
GlaxoSmithKline
Amir Reichman is stepping down.
Reichman is leaving his post as head of global vaccines engineering core technology at GSK to eventually head up operations at BiondVax Pharmaceuticals. Reichman will split duties with BiondVax’s founder and CEO Ron Babecoff until March 2 as he wraps his time at GSK. Reichman joined GSK in 2015 as part of a multibillion-dollar deal that saw GSK trade off its oncology assets for Novartis’ vaccines unit. Reichman held various positions at Novartis in its vaccine supply chain unit before becoming director of GSK’s global vaccines supply chain and then head of global ....

Charles River , United States , Ann Arbor , United Kingdom , Jay Meyer , Shehnaaz Suliman , Peter Emtage , Barrett Katz , Mark Fitzpatrick , Richard Woodman , Francesco Marincola , Fraiser Kansteiner , Acceleron Pharma , Frank Neumann , Joe Biden , Katz Bio Pharma , Eric Doherty , Steve Anderson , David Cronk , Amir Reichman , Ray Boffey , John Doyle , Robert Knight , Janet Woodcock , Eleanor Davies , Steven Tuch ,

Steven Tuch Joins Rallybio to Lead Corporate Development

Press release content from Business Wire. The AP news staff was not involved in its creation.
Steven Tuch Joins Rallybio to Lead Corporate Development
January 21, 2021 GMT
NEW HAVEN, Conn. (BUSINESS WIRE) Jan 21, 2021
Rallybio LLC, a clinical-stage biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Steven Tuch to lead the Company’s corporate development function. In this role, Mr. Tuch, a seasoned healthcare business professional, will have responsibility for Rallybio’s financing and capital allocation strategies and will also partner with the Business Development team to review and assess opportunities for transformative corporate deals, partnerships, and acquisitions. ....

New Haven , United States , Laura Ekas , Tara Dimilia , Steven Tuch , Deutsche Bank Securities , Business Services Equity Capital , Stanford University Graduate School Of Business , Health Care Equity Capital , Head Of Health Care Equity Capital , Business Development , University Of Michigan , Steve Uden , Chief Operating , Life Science , Managing Director , Capital Markets Originations , Care Equity Capital Markets , Health Care Equity Capital Markets , Business Services Equity Capital Markets , Equity Private , Stanford University , Graduate School , Technology Incubation Program , Business Wire , Corporate News ,